Preferences of patients and oncologists for the characteristics of the treatment for RCC in Spain and Portugal

30/05/2019
30/05/2019
EU PAS number:
EUPAS29920
Study
Planned
Study type

Study type

Non-interventional study

Scope of the study

Other

If ‘other’, further details on the scope of the study

Patients and oncologists preferences about treatment
Non-interventional study

Non-interventional study design

Cross-sectional
Study drug and medical condition

Medical condition to be studied

Renal cell carcinoma
Population studied

Age groups

  • Adults (18 to < 46 years)
  • Adults (46 to < 65 years)
  • Adults (65 to < 75 years)
  • Adults (75 to < 85 years)
  • Adults (85 years and over)

Estimated number of subjects

90
Study design details

Main study objective

The main objective of this project is to determine the preferences of patients and oncologists for the characteristics (attributes) of the treatment for renal cell carcinoma (RCC) in Spain and Portugal. In addition, factors contributing to their preferences will be evaluated.

Outcomes

To evaluate the differences and similarities among patients and oncologists’ preferences regarding RCC treatment attributes.To describe the sociodemographic and clinical characteristics of participants,To identify the characteristics of patients and oncologists which might explain their preferences for RCC treatment attributes.To estimate the willingness to accept a risk or to pay ...

Data analysis plan

A descriptive analysis of the socio-demographic and clinical characteristics of the participants will be performed. On the other hand, the results of the DCE (Discrete Choice Experiment) will be analyzed applying a mixed logit model. The influence of individual characteristics on participants' preferences will be explored through multiple linear regression. On the other hand, the correlation between the responses of patients and oncologists will be evaluated. In addition, the willingness to accept a less desirable risk or treatment characteristic in exchange for clinical benefit (MAR) as well as willingness to pay (WTP) will be analyzed.